Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare, the demand for innovative product commercialization and pricing models grows. In this webinar EVERSANA experts Robert Blank and Mike […]
The General Data Protection Regulation (GDPR) establishes a legal framework that sets guidelines for the collection and processing of personal information from individuals residing in the European Union (EU). GDPR compliance is a challenge for life science companies and services providers alike. Understanding and implementing compliance obligations under the GDPR is an ongoing process that […]
A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]
EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and State Legislature Update Increases in federal and state policies are putting more pressure on drug prices The possible removal […]
Clinical pathways that include CAR T-cell therapy as an option must integrate appropriate guidance on its use and settings of care.
(Content Updated 5/17) CMS Protected Class Rule Finalized, Slightly Loosened for Biopharma Following CMS’ 2018 proposed rule allowing for new protected class exceptions and a comment period for stakeholders through the beginning of this year, CMS has released a final rule addressing the Medicare Part D Protected Classes. The proposed rule allowed plans to restrict […]